Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences", stock code: 688321.SH) has officially received approval from the Drug Administration of Macao Special Administrative Region (ISAF) for the marketing of its independently developed original drug, Shuangluoping® ( Sitagliptin tablets). Previously, Epus® ( Chidamide tablets) was approved for marketing in Macao in January this year.
Sitagliptin, a blockbuster product in the company's metabolic field, has received marketing authorization for the first time in a market outside mainland China. This marks the company's expansion of its internationalization process into the vast metabolic disease market, following the successful export of its oncology products. Macau, as an important bridge between China and Portuguese-speaking countries, will lay a solid foundation for the product's subsequent entry into emerging markets such as Southeast Asia and South America. The successive approvals of two of Microchip Biotechnology's first-in-class drugs in Macau not only improve accessibility for local patients but also accumulate valuable international practical experience for the company's innovative drugs to participate in international competition through Macau as a "bridgehead."

Siglitazone
Chiglitazar Sodium
Product Name : Bilessglu®
The world's first approved PPAR pan-agonist can simultaneously and moderately activate three receptors—PPARα, PPARγ, and PPARδ—to regulate glucose, lipid, and energy metabolism balance. Sitagliptin has been approved for monotherapy and in combination with metformin for the treatment of type 2 diabetes. As the only PPAR pan-agonist included in the national medical insurance catalog, it has been included in more than ten authoritative guidelines/consensus documents, including the "Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition)," the "National Guidelines for the Prevention and Management of Diabetes at the Primary Level (2025 Edition)," and the "Expert Consensus on Combination Therapy of Oral Hypoglycemic Agents for Type 2 Diabetes in Adults (2025 Edition)."
Clinical studies have shown that sitagliptin can significantly improve insulin resistance and achieve sustained and stable blood glucose control. In terms of comprehensive metabolic regulation, sitagliptin can simultaneously reduce triglyceride levels and significantly reduce hepatic fat deposition, providing an effective comprehensive management solution for patients with diabetes and fatty liver.

Chidamide
Product Name : Epidaza®
This is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and China's first original anti-tumor chemical drug. Belonging to the epigenetic regulatory class of drugs, it reactivates the tumor-suppressive immune microenvironment and can be used alone or in combination with other drugs to treat malignant tumors, showing broad application prospects.
Chidamide has been included in the National Reimbursement Drug List (NRDL) under the routine Category B management. In China (covering mainland China, Macau, and Taiwan), it has been approved for three indications: peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma. In Japan, it has been approved for adult T-cell leukemia and peripheral T-cell lymphoma. Simultaneously, Chidamide is comprehensively advancing its pipeline, conducting multiple clinical studies in China and overseas, including Phase III trials for follicular helper T-cell phenotype peripheral T-cell lymphoma, Phase III trials for colorectal cancer, and Phase III trials for melanoma. Its strategy of combining with tumor immunotherapy (HDACi+IO) continues to be validated in multiple tumor types, and next-generation HDACi+IO drugs are also under development.

https://mp.weixin.qq.com/s/MhCOzAluL0dkGsREGzrWSw